Sera Prognostics (SERA) Projected to Post Quarterly Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA) will likely be announcing its Q4 2025 results after the market closes on Wednesday, March 18th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $0.0320 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 5:00 PM ET.

Sera Prognostics Trading Down 3.3%

Shares of NASDAQ:SERA opened at $2.06 on Tuesday. The company has a fifty day simple moving average of $2.72 and a 200 day simple moving average of $3.04. The firm has a market cap of $79.52 million, a PE ratio of -2.68 and a beta of 1.01. Sera Prognostics has a 12-month low of $1.37 and a 12-month high of $4.20.

Insider Activity

In related news, CEO Zhenya Lindgardt sold 22,639 shares of the firm’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $1.90, for a total transaction of $43,014.10. Following the transaction, the chief executive officer directly owned 741,287 shares in the company, valued at $1,408,445.30. This trade represents a 2.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last quarter, insiders sold 57,133 shares of company stock worth $115,794. Corporate insiders own 15.80% of the company’s stock.

Institutional Trading of Sera Prognostics

Several institutional investors have recently added to or reduced their stakes in the business. Lido Advisors LLC bought a new position in shares of Sera Prognostics in the 3rd quarter worth about $68,000. Cetera Investment Advisers bought a new stake in shares of Sera Prognostics during the 4th quarter valued at about $74,000. Qube Research & Technologies Ltd bought a new stake in shares of Sera Prognostics during the 2nd quarter valued at about $92,000. Two Sigma Investments LP acquired a new stake in Sera Prognostics during the third quarter worth about $97,000. Finally, Barclays PLC raised its stake in Sera Prognostics by 267.4% during the fourth quarter. Barclays PLC now owns 36,722 shares of the company’s stock worth $108,000 after acquiring an additional 26,726 shares during the period. Institutional investors own 54.64% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on SERA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Sera Prognostics in a report on Monday, December 29th. Jefferies Financial Group upgraded shares of Sera Prognostics to a “strong-buy” rating in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Sera Prognostics presently has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.